1COLLINS R,MACMAHON S.Blood pressure,antihypertensive drug treatment and the risks of stroke and of coronary heart disease[J].Br Med Bull,1994,50(1):272-298.
2SEVER P S,DAHLOF B,POULTER N R,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trim-Lipid Lowering Arm(ASCOT-LLA):a multicentre randomized controlled trial[J].Lancet,2003,361(9364):1149-1158.
3中国高血压防治指南(2005修订版)[M].北京:人民卫生出版社,2005.
4MANCIA G,DE BACKER G,DOMINICZAK A,et al.2007guidelines for the management of arterial hypertension:the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC)[J].Eur Heart J,2007,28(12):1462-1536.
5ROSENDORFF C,BLACK H R,CANNON C P,et al.Treatment of hypertension in the prevention and management of ischemic heart disease:a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention[J].Circulation,2007,115(21):2761-2788.
6中国成人血脂异常防治指南(2007)[M].北京:人民卫生出版社,2007.
7PARVING H H,LEHNERT H,BROCHNER-MORTENSEN J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
8KDOQI.Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J].AJKD,2007,49(2 Suppl 2):S13-S154.
9TAZEEN H,PAUL C,CHRISTOPHER H,et al.Progression of chronic kidney disease:the role of blood pressure control,proteinuria,and angiotensin-converting enzyme inhibition:a patient-level meta-analysis[J].Ann Intern Med,2003,139(4):244-252.
10ZEEUW D D,REMUZZI G,PARVING H H,et al.Albuminuria,a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy[J].Circulation,2004,110(8):921-927.
